Teens with Type 1 Diabetes and Executive Function Challenges Who Use Insulin Pumps Have Lower A1C Without Increased Risk of Diabetic Ketoacidosis or Severe Hypoglycemia.

IF 5.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Rebecca J Vitale, Liane J Tinsley, Lisa K Volkening, Lori M Laffel
{"title":"Teens with Type 1 Diabetes and Executive Function Challenges Who Use Insulin Pumps Have Lower A1C Without Increased Risk of Diabetic Ketoacidosis or Severe Hypoglycemia.","authors":"Rebecca J Vitale, Liane J Tinsley, Lisa K Volkening, Lori M Laffel","doi":"10.1089/dia.2024.0574","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Objective:</i></b> People with type 1 diabetes and executive function (EF) challenges (e.g., organization) often struggle with self-care. This study evaluated risks/benefits of insulin pumps in teens with EF challenges. <b><i>Research Design/Methods:</i></b> Parents of teens with type 1 diabetes completed parent-reported Behavior Rating Inventory of Executive Function. Severe hypoglycemia (SH) and diabetic ketoacidosis/hyperglycemia (DKA) events, collected prospectively, provided incidence rates (IR). A1c differences by pump use were compared by the presence/absence of EF challenges (Global Executive Composite score, EF indices). Adjusted multivariable models predicted A1c. Differences in SH and DKA IRs were evaluated by pump use and EF status, employing Poisson regressions. <b><i>Results:</i></b> In teens with EF challenges, pump-users versus nonusers had lower A1c (8.5% vs. 9.2%, <i>P</i> = 0.009). There were no A1c differences by pump use/nonuse in those without EF challenges. In multivariable analysis, A1c differences remained for those with EF challenges by one index; A1c was 0.65% lower in pump-users versus nonusers (<i>P</i> = 0.028). SH incidence did not differ by pump use or EF status. DKA incidence was lower in pump-users than nonusers (4.9 vs. 14.0 episodes/100-person-years, <i>P</i> = 0.012) and lower in teens without than with EF challenges (4.9 vs. 14.0/100-person-years, <i>P</i> = 0.012). In those without EF challenges, pump-users had lower DKA IR than nonpump-users (2.0 vs. 13.7/100-person-years, <i>P</i> = 0.003). In those with EF challenges, DKA IRs did not differ by pump use. <b><i>Conclusions:</i></b> Despite occasional prescriber hesitancy, teens with type 1 diabetes and EF challenges using insulin pumps had lower A1c without increased DKA risk compared with nonpump-users.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/dia.2024.0574","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: People with type 1 diabetes and executive function (EF) challenges (e.g., organization) often struggle with self-care. This study evaluated risks/benefits of insulin pumps in teens with EF challenges. Research Design/Methods: Parents of teens with type 1 diabetes completed parent-reported Behavior Rating Inventory of Executive Function. Severe hypoglycemia (SH) and diabetic ketoacidosis/hyperglycemia (DKA) events, collected prospectively, provided incidence rates (IR). A1c differences by pump use were compared by the presence/absence of EF challenges (Global Executive Composite score, EF indices). Adjusted multivariable models predicted A1c. Differences in SH and DKA IRs were evaluated by pump use and EF status, employing Poisson regressions. Results: In teens with EF challenges, pump-users versus nonusers had lower A1c (8.5% vs. 9.2%, P = 0.009). There were no A1c differences by pump use/nonuse in those without EF challenges. In multivariable analysis, A1c differences remained for those with EF challenges by one index; A1c was 0.65% lower in pump-users versus nonusers (P = 0.028). SH incidence did not differ by pump use or EF status. DKA incidence was lower in pump-users than nonusers (4.9 vs. 14.0 episodes/100-person-years, P = 0.012) and lower in teens without than with EF challenges (4.9 vs. 14.0/100-person-years, P = 0.012). In those without EF challenges, pump-users had lower DKA IR than nonpump-users (2.0 vs. 13.7/100-person-years, P = 0.003). In those with EF challenges, DKA IRs did not differ by pump use. Conclusions: Despite occasional prescriber hesitancy, teens with type 1 diabetes and EF challenges using insulin pumps had lower A1c without increased DKA risk compared with nonpump-users.

1型糖尿病和执行功能障碍的青少年使用胰岛素泵可以降低糖化血红蛋白,但不会增加糖尿病酮症酸中毒或严重低血糖的风险。
目的:患有1型糖尿病和执行功能(EF)挑战的人(例如,组织能力)经常在自我照顾方面挣扎。本研究评估了胰岛素泵治疗EF障碍青少年的风险/益处。研究设计/方法:1型糖尿病青少年的父母完成父母报告的执行功能行为评定量表。前瞻性收集的严重低血糖(SH)和糖尿病酮症酸中毒/高血糖(DKA)事件提供了发病率(IR)。通过存在/不存在EF挑战(全球执行综合评分,EF指数)来比较泵使用的A1c差异。调整后的多变量模型预测A1c。SH和DKA ir的差异通过泵使用和EF状态进行评估,采用泊松回归。结果:在有EF障碍的青少年中,泵使用者比非使用者的A1c更低(8.5%比9.2%,P = 0.009)。在没有EF挑战的患者中,使用/不使用泵的A1c没有差异。在多变量分析中,EF挑战患者的A1c在一个指标上仍然存在差异;与不使用泵的患者相比,使用泵的患者A1c降低0.65% (P = 0.028)。SH发生率没有因泵的使用或EF状态而异。泵使用者的DKA发生率低于非泵使用者(4.9 vs. 14.0次/100人年,P = 0.012),没有EF挑战的青少年的DKA发生率低于未EF挑战的青少年(4.9 vs. 14.0/100人年,P = 0.012)。在没有EF挑战的患者中,泵使用者的DKA IR低于非泵使用者(2.0 vs. 13.7/100人年,P = 0.003)。在那些有EF挑战的患者中,DKA ir没有因使用泵而不同。结论:与未使用胰岛素泵的青少年相比,尽管偶尔会出现处方犹豫,但使用胰岛素泵的1型糖尿病和EF挑战青少年的A1c较低,且DKA风险未增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信